Clinical Trials Logo

Clinical Trial Summary

This longitudinal study will focus on the cognitive and brain development of children with absence epilepsy. In addition, the investigators aim to identify prognostic factors for cognitive deterioration and/or poor seizure control in these children.


Clinical Trial Description

The aim is to study the cognitive and brain development of children with absence epilepsy. In addition, this study aims to identify prognostic factors for cognitive deterioration and/or poor seizure control.

Objective:

1. To study the development of cognition in children with absence epilepsy and the functional brain organization over time.

2. To find prognostic factors in terms of clinical, 24h-video-EEG or/and MRI characteristics for cognitive deterioration and/or poor seizure control in patients with absence epilepsy.

Study design:

2 year prospective longitudinal, controlled, comparative, clinical, follow up.

Study population:

60 children with recently diagnosed (<2 years) absence epilepsy, aged 6 to 12 years. In addition, this study includes a control group of 15 age and gender matched healthy volunteers.

Main study parameters/endpoints:

Endpoints are the development of clinical parameters (semiology, 24h-video-EEG and seizure control), neuropsychological/behavioural outcomes, structural/functional MRI parameters, and educational performance. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02954107
Study type Observational [Patient Registry]
Source Maastricht University Medical Center
Contact Eric LA Fonseca Wald, MD
Phone +31 (0)43 387 65 84
Email LEES.studie.kinderneurologie@mumc.nl
Status Recruiting
Phase
Start date September 2016
Completion date January 2020

See also
  Status Clinical Trial Phase
Completed NCT04615442 - ECV - Epihunter Clinical Validation N/A
Completed NCT04439656 - Detecting Absence Seizures Using Eye Tracking
Recruiting NCT06093490 - Detecting Absence Seizures Using Hyperventilation and Eye Movement Recordings
Recruiting NCT04274179 - Ketogenic Diet for New-Onset Absence Epilepsy Phase 3